2509 related articles for article (PubMed ID: 28796882)
61. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia.
Shipitsyna E; Zolotoverkhaya E; Kuevda D; Nasonova V; Romanyuk T; Khachaturyan A; Orlova O; Abashova E; Kostyuchek I; Shipulina O; Anttila A; Savicheva A
Cancer Epidemiol; 2011 Apr; 35(2):160-4. PubMed ID: 20884314
[TBL] [Abstract][Full Text] [Related]
62. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
63. Performance of OncoE6
Ndizeye Z; Menon S; Van Geertruyden JP; Sauvaget C; Jacquemyn Y; Bogers JP; Benoy I; Vanden Broeck D
BMJ Open; 2019 Sep; 9(9):e029088. PubMed ID: 31494606
[TBL] [Abstract][Full Text] [Related]
64. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
65. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
66. Cervical Cancer Screening: Comparison of Conventional Pap Smear Test, Liquid-Based Cytology, and Human Papillomavirus Testing as Stand-alone or Cotesting Strategies.
Liang LA; Einzmann T; Franzen A; Schwarzer K; Schauberger G; Schriefer D; Radde K; Zeissig SR; Ikenberg H; Meijer CJLM; Kirkpatrick CJ; Kölbl H; Blettner M; Klug SJ
Cancer Epidemiol Biomarkers Prev; 2021 Mar; 30(3):474-484. PubMed ID: 33187968
[TBL] [Abstract][Full Text] [Related]
67. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
[TBL] [Abstract][Full Text] [Related]
68. Performance of ProEx C and PreTect HPV-Proofer E6/E7 mRNA tests in comparison with the hybrid capture 2 HPV DNA test for triaging ASCUS and LSIL cytology.
Alaghehbandan R; Fontaine D; Bentley J; Escott N; Ghatage P; Lear A; Coutlee F; Ratnam S
Diagn Cytopathol; 2013 Sep; 41(9):767-75. PubMed ID: 23341349
[TBL] [Abstract][Full Text] [Related]
69. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
70. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
71. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
[TBL] [Abstract][Full Text] [Related]
72. Test positivity cutoff level of a high risk human papillomavirus test could be increased in routine cervical cancer screening.
Kotaniemi-Talonen L; Malila N; Nieminen P; Anttila A; Tarkkanen J; Laurila P; Hakama M
Int J Cancer; 2008 Dec; 123(12):2902-6. PubMed ID: 18792100
[TBL] [Abstract][Full Text] [Related]
73. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
[TBL] [Abstract][Full Text] [Related]
74. High-risk Human Papillomavirus Testing for Triage of Women with Previous Cytological Abnormalities from the Vale do Ribeira Region.
Lorente S; Fernandes NCCA; Etlinger-Colonelli D; Réssio RA; Oliveira SMP; Catarino RM
Rev Bras Ginecol Obstet; 2020 Jun; 42(6):340-348. PubMed ID: 32604437
[TBL] [Abstract][Full Text] [Related]
75. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.
Kreimer AR; Guido RS; Solomon D; Schiffman M; Wacholder S; Jeronimo J; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):908-14. PubMed ID: 16702369
[TBL] [Abstract][Full Text] [Related]
76. Pooled analysis of the performance of liquid-based cytology in population-based cervical cancer screening studies in China.
Pan QJ; Hu SY; Zhang X; Ci PW; Zhang WH; Guo HQ; Cao J; Zhao FH; Lytwyn A; Qiao YL
Cancer Cytopathol; 2013 Sep; 121(9):473-82. PubMed ID: 23907807
[TBL] [Abstract][Full Text] [Related]
77. Performance of self-sampled HPV test in comparison with liquid based cytology.
Igidbashian S; Boveri S; Radice D; Casadio C; Spolti N; Sandri MT; Sideri M
Eur J Obstet Gynecol Reprod Biol; 2014 Jun; 177():72-6. PubMed ID: 24768230
[TBL] [Abstract][Full Text] [Related]
78. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
[TBL] [Abstract][Full Text] [Related]
79. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland.
Leinonen MK; Nieminen P; Lönnberg S; Malila N; Hakama M; Pokhrel A; Laurila P; Tarkkanen J; Anttila A
BMJ; 2012 Nov; 345():e7789. PubMed ID: 23197596
[TBL] [Abstract][Full Text] [Related]
80. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
